Biocryst Pharmaceuticals Inc Stock Price, News & Analysis

BioCryst Pharmaceuticals reported Q4 2022 net revenue of $70.7 million, with a full-year total of $251.6 million, reflecting a 72% year-over-year increase. The company projects 2023 revenue for ORLADEYO to reach no less than $320 million, anticipating peak sales of $1 billion. Financial results revealed a net loss of $71.5 million in Q4, up from $17.8 million a year prior. Total cash and investments as of December 31, 2022, stood at $443.9 million. R&D and SG&A expenses increased, attributed to higher investments for ORLADEYO's launch and ongoing programs. The company is focused on expanding its market reach with robust demand for ORLADEYO, now available in 15 countries.

BioCryst Pharmaceuticals (Nasdaq: BCRX) announces it will report Q4 2022 financial results on February 21, 2023. The management will host a conference call at 8:30 a.m. ET to discuss results and provide a corporate update. Investors can access the live call by dialing 1-866-777-2509 (domestic) or 1-412-317-5413 (international). A live webcast and replay will be available on the company’s website. BioCryst focuses on developing oral, small-molecule medicines for rare diseases with significant unmet medical needs, including products like ORLADEYO® and RAPIVAB®.

BioCryst Pharmaceuticals (BCRX) has granted stock options and restricted stock units (RSUs) to 20 newly-hired employees as part of their incentive compensation plan. A total of 287,200 stock options and 101,700 RSUs will vest annually over four years, with a set exercise price of $10.55 per share, equating to the stock's closing price on the grant date of January 31, 2023. These grants comply with Nasdaq regulations. BioCryst focuses on developing novel medications for rare diseases, including ORLADEYO and RAPIVAB, both approved in various markets. For further details, visit their website.

BioCryst Pharmaceuticals (Nasdaq: BCRX) announced its presentation of four abstracts on ORLADEYO (berotralstat), aimed at preventing hereditary angioedema (HAE) attacks, during the 2023 AAAAI annual meeting in San Antonio, Texas, from February 24-27. Highlights include new analyses from the long-term clinical program and real-world evidence indicating significant reductions in attack rates and improvements in the quality of life for patients. The abstracts will be presented on February 26 and are accessible in The Journal of Allergy and Clinical Immunology. ORLADEYO is the first oral therapy specifically designed for HAE prophylaxis.

BioCryst Pharmaceuticals (Nasdaq: BCRX) has initiated the pivotal APeX-P trial, enrolling its first pediatric patient for the oral therapy ORLADEYO® (berotralstat) aimed at treating hereditary angioedema (HAE) in children aged 2 to <12 years. The trial will assess the pharmacokinetics and safety of ORLADEYO, following a 12-week standard-of-care period, leading into an open-label phase of 48 weeks and potentially extending to 144 weeks. The information gathered will support a supplemental New Drug Application (sNDA) for expanding ORLADEYO's use in pediatric patients. ORLADEYO is the first oral preventive therapy approved for HAE attacks in patients aged 12 years and older.

BioCryst Pharmaceuticals (BCRX) announced a collaboration with Swixx BioPharma AG to commercialize ORLADEYO (berotralstat) in Central and Eastern Europe (CEE). This partnership aims to make this oral prophylactic treatment for hereditary angioedema accessible to patients in 15 CEE markets. BioCryst is focused on addressing significant unmet needs in rare diseases, and Swixx brings extensive expertise in this area. The agreement highlights the commercialization efforts for a therapy that is the first oral treatment specifically designed to prevent HAE attacks in adults and children aged 12 and older.

BioCryst Pharmaceuticals (BCRX) reported preliminary ORLADEYO net revenue of $251.6 million for 2022, reflecting a 105% year-over-year increase. The fourth quarter generated $70.7 million in net revenue, a 53% increase from the previous year. Looking ahead, the company projects 2023 revenue to reach at least $320 million and anticipates peak ORLADEYO sales of $1 billion. Company executives noted strong market performance despite slight revenue lag due to seasonal factors.

BioCryst Pharmaceuticals (BCRX) announced promising initial data from its phase 1 trials for BCX10013, a potential best-in-class oral Factor D inhibitor targeting complement-mediated diseases. The trials demonstrated a sustained suppression of the alternative pathway by over 97% following a single dosage, indicating its safety and effectiveness. Plans are set to advance to patient studies for conditions like paroxysmal nocturnal hemoglobinuria (PNH) and immunoglobulin A nephropathy (IgAN). Additionally, the company is expanding its research on oral therapies for other complement pathways.

BioCryst Pharmaceuticals (Nasdaq: BCRX) announced its participation in the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023, at 6:00 p.m. ET in San Francisco. The event will feature a presentation from the company, and a live audio webcast will be accessible on their website. BioCryst specializes in developing oral medicines for rare diseases, including its approved product ORLADEYO (berotralstat) and RAPIVAB (peramivir injection). The company is also advancing multiple therapeutic projects, including BCX10013.